Synageva Announces $80M Proposed Offering of Common Stock

Synageva BioPharma Corp. (“Synageva”)

, a clinical stage biopharmaceutical company developing therapeutic products for rare disorders, today announced that it has commenced a $80 million underwritten public offering of shares of its common stock. In connection with this offering, Synageva expects to grant to the underwriters a 30-day option to purchase additional shares of common stock, equal to up to 15% of the number of shares of common stock sold in the offering. Morgan Stanley and J.P. Morgan are acting as joint book-running managers in the offering, and Cowen and Company is acting as co-manager in the offering. The securities described above are being offered by Synageva pursuant to a Form S-3 shelf registration